The techniques of molecular biology will be used to determine normal apo B gene structure as well as variation in the apo B gene that might underlie certain dyslipoproteinemias as well as atherosclerosis susceptibility.
The specific aims are in two sections: 1) To determine the structure of the apo B gene. Utilizing a liver cDNA expression library and polyclonal antisera to LDL, cDNA clones corresponding to apo B 1,500-1,600bp in length have been isolated. Northern blot analysis showed hepatic apo B mRNA to be 22kb in length, which means that the cDNA clones represent only 7% of apo B mRNA. Preliminary analysis indicates that the cDNA clones correspond to the region coding for the carboxy terminal 300-350 amino acids of apo B as well as the 3' untranslated region. To identify total apo B mRNA structure, these initial cDNA clones will be used as primers for extension on a template of HepG2 cell mRNA to allow cloning of additional cDNA sequences. Due to the length of apo B mRNA, this will have to be done in multiple steps to obtain cDNA corresponding to the most 5' portion of the apo B mRNA. These studies will allow us to deduce the primary amino acid sequence of apo B. The isolated cDNA clones will also be used to isolate from bacteriophage lambda and cosmid libraries clones containing apo B genomic regions. In this manner, the length of the apo B gene and its exon/intron configuration will be determined. Two subprojects will be emphasized: a) determining the relationship of B-48 and B-100, b) identification and characterization of the receptor-binding region. 2) to define human genetic variation in apo B. We intend to map apo B in the human genome and to use various probes for different regions of the apo B gene to identify restriction fragment length polymorphisms (RFLPs) that might be useful in clinical studies. We intend to see if any of these polymorphisms are associated with dyslipoproteinemia and/or atherosclerosis susceptibility. These RFLPs will also be useful in family studies to determine linkage of the apo B gene to a parameter that might segregate in a given family family such as atherosclerosis susceptibility or lipoprotein abnormality. Apo B gene abnormalities will be specifically sought in several human lipoprotein disorders, such as hyperapobetalipoproteinemia, abetalipoproteinemia, and normotriglyceridemic abetalipoproteinemia. If the abnormality in these disorders resides in the apo B gene, their specific molecular basis will be determined.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37HL036461-02
Application #
3486110
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
1986-04-01
Project End
1991-03-31
Budget Start
1987-04-01
Budget End
1988-03-31
Support Year
2
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Rockefeller University
Department
Type
Graduate Schools
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Huang, L S; Voyiaziakis, E; Markenson, D F et al. (1995) apo B gene knockout in mice results in embryonic lethality in homozygotes and neural tube defects, male infertility, and reduced HDL cholesterol ester and apo A-I transport rates in heterozygotes. J Clin Invest 96:2152-61
Heinemann, T; Metzger, S; Fisher, E A et al. (1994) Alternative polyadenylation of apolipoprotein B RNA is a major cause of B-48 protein formation in rat hepatoma cell lines transfected with human apoB-100 minigenes. J Lipid Res 35:2200-11
Brinton, E A; Eisenberg, S; Breslow, J L (1994) Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution Arterioscler Thromb 14:707-20
Breslow, J L (1992) Apolipoprotein genes and atherosclerosis. Clin Investig 70:377-84
Huang, L S; Kayden, H; Sokol, R J et al. (1991) ApoB gene nonsense and splicing mutations in a compound heterozygote for familial hypobetalipoproteinemia. J Lipid Res 32:1341-8
Brinton, E A; Eisenberg, S; Breslow, J L (1991) Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 87:536-44
Chajek-Shaul, T; Hayek, T; Walsh, A et al. (1991) Expression of the human apolipoprotein A-I gene in transgenic mice alters high density lipoprotein (HDL) particle size distribution and diminishes selective uptake of HDL cholesteryl esters. Proc Natl Acad Sci U S A 88:6731-5
Breslow, J L (1991) Lipoprotein transport gene abnormalities underlying coronary heart disease susceptibility. Annu Rev Med 42:357-71
Hayek, T; Chajek-Shaul, T; Walsh, A et al. (1991) Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprotein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice. Arterioscler Thromb 11:1295-302
Zechner, R; Newman, T C; Steiner, E et al. (1991) The structure of the mouse lipoprotein lipase gene: a B1 repetitive element is inserted into the 3' untranslated region of the mRNA. Genomics 11:62-76

Showing the most recent 10 out of 32 publications